ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) EBIT : HK$-413.38 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) EBIT?

ImmuneOnco Biopharmaceuticals (Shanghai)'s earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$-227.22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-413.38 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized ROC % for the quarter that ended in Dec. 2023 was -146.62%. ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -316.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ImmuneOnco Biopharmaceuticals (Shanghai)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.88%.

ImmuneOnco Biopharmaceuticals (Shanghai) EBIT Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) EBIT Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

EBIT

-896.38

-449.04

-413.38

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	-	-247.66	-213.11	-186.16	-227.22

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s EBIT

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-EBIT falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-413.38 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-429.756 * ( 1 - 0% )	/	( (274.167	+	312.059)	/ 2 )
=	-429.756	/	293.113
=	-146.62 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	799.416	-	6.763	-	( 589.9	-	max(0, 80.93	-	599.416	+	589.9	))
=	274.167

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	956.608	-	20.229	-	( 665.634	-	max(0, 126.778	-	751.098	+	665.634	))
=	312.059

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-454.432	/	( ( (167.613 + max(-33.629, 0))	+	(91.793 + max(27.964, 0)) )	/	2 )
=	-454.432	/	( ( 167.613	+	119.757 )	/	2 )
=	-454.432	/	143.685
=	-316.27 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.004	+	0	+	9.2270000000001)	-	(6.763	+	0	+	36.097)
=	-33.629

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.043	+	0	+	84.284)	-	(20.229	+	0	+	36.134)
=	27.964

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ImmuneOnco Biopharmaceuticals (Shanghai)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-413.377	/	4656.257
	=	-8.88 %

ImmuneOnco Biopharmaceuticals (Shanghai) EBIT Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines